Shares of POET Technologies tumbled as much as 10.6% to $14.27 on May 18 after the optical chipmaker announced a $400 million registered direct offering, triggering a wave of profit-taking from investors who had ridden the stock's dramatic surge from roughly $10 to over $20 in barely a week. POET's $400 Million Cash Grab: Smart Growth Fuel or a Painful Dilution Pill for Shareholders?
Shares of POET Technologies slid 10.6% to $14.27 on Monday as the optical chip designer closed a massive $400 million equity raise, colliding with profit-taking after a meteoric 320%-plus rally from March lows. The deal, which closed today, issued 19,047,620 new common shares and an equal number of warrants to a single institutional investor, raising gross proceeds of $400 million. The timing is telling: POET struck while its stock was white-hot, but investors are now doing the math on what their ownership is actually worth.
• Nearly 19 Million New Shares Hit the Market — With 19 Million More Lurking Behind Warrants
POET had roughly 152.7 million shares outstanding before the deal, a figure already up 54.6% over the past year. The offering adds 19 million shares immediately — a ~12.5% jump — and the warrants, exercisable at $26.15 per share over three years , could eventually push the total increase to ~25%. That means every existing shareholder's slice of the pie just got meaningfully smaller.
• The Price Tag Looked Like a Premium, but the Stock Has Already Fallen Below It
The $21.00 per-unit price was set at a premium to the May 14 NASDAQ close of $20.57. But POET now trades at $14.27 — fully 32% below the offering price — meaning the institutional buyer is already underwater and existing holders who bought during last week's spike are nursing steep losses.
• Revenue Is Growing Fast Off a Tiny Base, and Losses Are Widening
Q1 2026 results showed an adjusted loss of $0.08 per share, $0.03 worse than analysts expected, while revenue of $0.5 million rose 194% year-over-year but still barely registers.
POET trades at a price-to-sales ratio of roughly 2,922x , a valuation that assumes enormous future growth. A new partnership framework could deliver over $500 million in cumulative orders , but only $50 million is committed initially, with engineering samples targeted for late 2026.
• $400 Million Buys Time, but Execution Is the Real Test
Proceeds are earmarked for manufacturing expansion, targeted acquisitions, R&D, and working capital.
Meanwhile, the CFO who guided finances for a decade plans to retire this year , adding leadership uncertainty at a critical scaling moment. For a company with an accumulated deficit near $291 million , this cash injection buys serious runway — if management can convert partnership promises into real shipments before the next dilution event.